Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE:BMY) launched the “Investigating Myeloma” awareness campaign with actor and advocate Mariska Hargitay, honoring her father 20 years after his death from multiple myeloma.
The campaign highlights unmet needs in this incurable blood cancer and showcases BMS-led CELMoD targeted protein degradation research aimed at engaging cereblon to break down disease‑related proteins, stimulate the immune system, and enhance cancer cell killing.
Arcus Biosciences (NYSE:RCUS) entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY) to evaluate casdatifan, an investigational HIF-2a inhibitor, in the Phase 1/2 ROSETTA RCC-208 trial for advanced renal cell carcinoma.
Casdatifan will be added as two new trial arms in combination with pumitamig, an investigational PD-L1/VEGF-A bispecific antibody. Each company keeps development and commercial rights, and the agreement is mutually non-exclusive.
Bristol Myers Squibb (NYSE:BMY) and SystImmune reported prespecified interim Phase 3 results for izalontamab brengitecan (iza-bren) in triple-negative breast cancer (TNBC) and esophageal squamous cell carcinoma (ESCC).
Iza-bren improved overall survival, progression-free survival and objective response rates versus chemotherapy, with manageable safety, and an ESCC New Drug Application under priority review in China.
Bristol Myers Squibb (NYSE:BMY) announced that the U.S. FDA has accepted for Priority Review a supplemental New Drug Application for Camzyos (mavacamten) to treat adolescents aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The sNDA is supported by the Phase 3 SCOUT-HCM trial, which met its primary endpoint, and a safety profile similar to adults, with no patients experiencing LVEF <50%. The FDA set a PDUFA date of September 30, 2026.
Bristol Myers Squibb (NYSE:BMY) received European Commission approval for Opdivo (nivolumab) + AVD as first-line treatment for adult and adolescent patients ≥12 years with previously untreated Stage III/IV classical Hodgkin lymphoma.
SWOG 1826 showed a 58% reduction in risk of progression or death versus brentuximab vedotin + AVD (HR 0.42).
Bristol Myers Squibb (NYSE:BMY) reported Phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib/dexamethasone (MeziKd) significantly improved outcomes in relapsed/refractory multiple myeloma versus carfilzomib/dexamethasone (Kd).
MeziKd achieved median progression-free survival of 18 vs 8.3 months (HR 0.48; p<0.0001), a 52% lower risk of progression or death, with higher response rates but more grade 3-4 neutropenia and infections.
Bristol Myers Squibb (NYSE:BMY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Management will join a fireside chat at 2:00 p.m. ET, with a live audio webcast and archived replay available via the company’s investor relations website.
Bristol Myers Squibb (NYSE:BMY) will present more than 60 oncology disclosures, including 19 oral presentations, at the ASCO 2026 meeting from May 29–June 2 in Chicago.
Key highlights include late-breaking Phase 3 mezigdomide SUCCESSOR-2 multiple myeloma data, Phase 3 iza-bren breast and esophageal cancer trials, Phase 2 pumitamig in first-line NSCLC, and new Breyanzi real-world outcomes, alongside detailed Breyanzi indication and safety information.
Bristol Myers Squibb (NYSE:BMS) announced a strategic agreement with Anthropic to deploy Claude Enterprise as a shared intelligence platform across global operations. More than 30,000 employees are expected to use Claude’s agentic capabilities across research, clinical development, manufacturing, commercial and corporate functions.
Priorities include accelerating engineering with Claude Code, embedding AI agents into drug discovery and development workflows, enhancing manufacturing quality and compliance, improving medical and commercial engagement, and securely connecting decades of proprietary scientific, molecular and clinical data under enterprise governance and audit controls.
Bristol Myers Squibb (NYSE: BMY) and Tempus AI announced an expanded collaboration using AI, multimodal real-world data, and the Tempus Lens platform to optimize clinical trial design and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial development programs.
The initiative supports solid tumor oncology assets in lung, colon, and prostate cancers and extends into neuroscience for Alzheimer’s disease. It focuses on refining trial assumptions, characterizing complex patient populations, validating control groups, and identifying optimal patient segments for investigational therapies.